Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →ExonHit/Diaxonhit confirmed Allergan sublicensed the asset to BMS for $40M upfront plus up to $373M in milestones — a structure that gave BMS a low-cost option…
The Allergan-BMS pact was framed as a complementary fit with BMS's existing neuroscience strategy and Allergan's preference for partnering rather than building…
Diaxonhit was informed by Allergan that BMS decided to stop development of EHT/AGN 0001 and returned the program; reasons for the decision were not…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS/Allergan global exclusive license for AGN-209323: $40M upfront + up to $373M milestones + worldwide royalties. Originally licensed from ExonHit.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Allergan, Inc. (EHT/AGN 0001 license) (this deal) | 2010 | $413M | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2010 deals · Bristol-Myers Squibb Company deals · Neurology deals